Cost-Utility Analysis of Dexrazoxane Combined with Doxorubicin Versus Doxorubicin Liposomes for the Prevention of Chemotherapy-Induced Cardiotoxicity in Patients with Advanced Breast Cancer
Objective To evaluate the economics of dexrazoxane combined with doxorubicin versus doxorubicin liposomes for the prevention of chemotherapy-induced cardiotoxicity in patients with advanced breast cancer.Methods The decision tree model of dexrazoxan combined with doxorubicin versus doxorubicin liposomes for the prevention of chemotherapy-induced cardiotoxicity in patients with advanced breast cancer was constructed.Combined analysis and indirect comparison were conducted for extracting data from the original literature to obtain the safety data and effectiveness data.Direct medical costs and quality-adjusted life years(QALYs)for the two decisions were calculated by available information about costs-utility value.Cost-utility analysis was used to compare the two strategies.The sensitivity analysis was performed to evaluate the robustness of the results.Results Compared with that of doxorubicin liposomes,the cost of dexrazoxane combined with doxorubicin was lower,while the QALY was higher.Sensitivity analysis indicated the results were robust.Conclusion Compared with doxorubicin liposomes,dexrazoxane combined with doxorubicin was a more economic therapy for the prevention of chemotherapy-induced cardiotoxicity in patients with advanced breast cancer.
dexrazoxanedoxorubicindoxorubicin liposomesadvanced breast cancercardiotoxicitycost-utility analysis
万方数据
